<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01603264</url>
  </required_header>
  <id_info>
    <org_study_id>B3271001</org_study_id>
    <secondary_id>REFLECTIONS B327-01</secondary_id>
    <nct_id>NCT01603264</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)</brief_title>
  <official_title>Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-05280014 And Trastuzumab Sourced From US And EU Administered To Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, healthy male volunteers will receive a single intravenous administration of
      either PF-05280014 or trastuzumab (United States) or trastuzumab (European Union). During the
      course of the study, the pharmacokinetics will be assessed by sampling the levels of drug in
      the blood, and by comparing these levels among the different administration arms of
      PF-05280014 and the US-licensed and EU-approved trastuzumab products. Safety, tolerability,
      and immunologic response also will be evaluated throughout.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters Area-Under-the-Curve (AUC) and Maximal Concentration (Cmax) of PF-05280014 compared to trastuzumab-EU.</measure>
    <time_frame>Day 1 - Day 71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters Area-Under-the-Curve (AUC) and Maximal Concentration (Cmax) of PF-05280014 compared to trastuzumab-US.</measure>
    <time_frame>Day 1 - Day 71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters Area-Under-the-Curve (AUC) and Maximal Concentration (Cmax) of trastuzumab-EU to trastuzumab-US.</measure>
    <time_frame>Day 1 - Day 71</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-trastuzumab antibodies (ADAs), including neutralizing antibodies (Nab).</measure>
    <time_frame>Day 1 - LSLV or Day 71 whichever occurs later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters Maximal Concentration (Cmax) and Area-Under-the-Curve (AUC) for the combined groups of trastuzumab-US and trastuzumab EU.</measure>
    <time_frame>Day 1 - Day 71</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05280014</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trastuzumab-EU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trastuzumab-US</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05280014</intervention_name>
    <description>Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Trastuzumab-Pfizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Trastuzumabum (European Union)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Trastuzumab (United States)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects (healthy is defined as no clinically relevant abnormalities
             identified by a detailed medical history, full physical examination including blood
             pressure and pulse rate measurement, 12-lead ECG, and clinical laboratory tests). Body
             Mass Index (BMI) of 17.5 to 30.5 kg/m2 and a total body weight &gt; 50 kg (110 lbs).

          -  Male subjects must agree that they and their female spouse/partners will use adequate
             contraception (2 forms of birth control, one of which must be barrier method) or be of
             non-childbearing potential.

          -  Left ventricular ejection fraction (LVEF) within the normal range as measured by
             echocardiogram (ECHO) within 8 weeks prior to randomization.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or
             allergic disease, or clinical findings at screening excluding untreated, asymptomatic
             seasonal allergies at time of dosing.

          -  Clinically significant abnormalities in laboratory test results.

          -  Previous exposure to a monoclonal antibody or current use of other biologics.

          -  History of allergic or anaphylactic reaction to a therapeutic drug or benzyl alcohol.

          -  Use of prescription or non prescription drugs and dietary supplements within 7 days or
             5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal
             supplements must be discontinued 28 days prior to the first dose of study medication.

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the investigator, would make the subject
             inappropriate for entry into this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3271001&amp;StudyName=A%20Pharmacokinetic%20Study%20Comparing%20PF-05280014%20And%20Trastuzumab%20In%20Healthy%20Male%20Volunteers%20%28REFLECTIONS%20B327-01%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2012</study_first_submitted>
  <study_first_submitted_qc>May 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2012</study_first_posted>
  <last_update_submitted>December 15, 2012</last_update_submitted>
  <last_update_submitted_qc>December 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Biosimilarity</keyword>
  <keyword>Similarity</keyword>
  <keyword>PK</keyword>
  <keyword>Phase I</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Healthy Male Volunteers</keyword>
  <keyword>Single-dose</keyword>
  <keyword>HER-2</keyword>
  <keyword>Oncology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

